For an e-mail response to your Regeneron investment question, please contact us at invest@regeneron.com.

Regeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions. In addition to ARCALYST(R) (rilonacept) Injection for Subcutaneous Use, its first commercialized product, Regeneron has therapeutic candidates in Phase 3 clinical trials for the potential treatment of gout, age-related macular degeneration, and certain cancers. Additional therapeutic candidates are in earlier stage development programs in rheumatoid arthritis and other inflammatory conditions, pain, cholesterol reduction, allergic conditions, and cancer.

Recent Events
Aug 13, 2010	Bank of America Merrill Lynch 2010 Specialty Pharmaceuticals Conference View Presentation
Jul 15, 2010	Regeneron 2010 Investor Day Note: These videos were shown at the meeting but not webcast. You may view them here at any time. VelociGene® and VelocImmune® Technologies: A Brief History Process Development and Manufacturing Introduction: Leonard Schleifer, M.D., Ph.D., Chief Executive Officer R&D Overview: George Yancopoulos, M.D., Ph.D., Chief Scientific Officer Early Clinical Development: Neil Stahl, Ph.D., Senior Vice President, Research and Development Sciences Early Stage Development: Peter Powchik, M.D., Senior Vice President, Clinical Development Oncology: Alain Thibault, M.D., Vice President, Clinical Sciences, Oncology VEGF Trap–Eye: Robert Vitti, M.D., Executive Director, Clinical Sciences, Ophthalmology ARCALYST® (rilonacept): Bob Terifay, Senior Vice President, Commercial Financial Overview: Murray Goldberg, Chief Financial Officer Industrial Operations and Product Supply: Dan Van Plew, Senior Vice President, Industrial Operations and Product Supply
View all events & presentations »